Navigation Links
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/3/2008

- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly -

SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of its third cohort of patients in a Phase 1 clinical trial of new HspE7 (HspE7 + Poly-ICLC) in patients with cervical intraepithelial neoplasia (CIN). The safety data from the cohort were normal and met the limits prescribed in the trial protocol, allowing advancement to the fourth cohort of patients in the study.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

The evaluation by the Safety Review Committee was performed after the third cohort reached five weeks of treatment (two doses plus one week of follow-up). The dosing of the fourth cohort of patients is expected shortly.

At the end of each cohort, Nventa is also collecting immunological data that may provide an early indication of potential efficacy of the compound. All patients are being typed for class I and II human leukocyte antigen (HLA) subtypes, and are being evaluated for cytokine responses, anti-HspE7 antibodies and cellular (T-cell) immunology.

The trial is expected to dose up to 5 cohorts comprising twenty-four patients. The first cohort of patients was administered 500 mcg of HspE7 and 50 mcg of adjuvant containing Poly-IC, a toll-like receptor-3 (or TLR3) agonist. The second cohort was administered 500 mcg of HspE7 and an escalated dose of 500 mcg of adjuvant. The third cohort was administered 500 mcg of HspE7 and 1,000 mcg of adjuvant. The fourth cohort will be administered 500 mcg of HspE7 and 2,000 mcg of adjuvant. An additional cohort of patients administered 1,000 mcg of HspE7 and 2,000 mcg of adjuvant may be added if deemed appropriate based on data from the previous four cohorts.

Following successful completion of th
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... MOUNTAIN VIEW, Calif. , Oct. 31, 2014 /PRNewswire/ ... amyotrophic lateral sclerosis (ALS) patients initiate text and email ... based upon a patent-pending technology invented by ThynkWare,s founder, ... virtual assistant on a smartphone device. This technology allows ... ways using only the power of thought. ...
(Date:10/31/2014)... 2014 Migranade, Inc. announced today the new ... the 36 million U.S. migraine sufferers November, 2014. The ... the actual cause of migraines and not just the ... the source Migranade is assured to be a game ... is available at http://www.migranade.com and will soon ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2Game Changing Migraine Medication To Be Available November 2014 2
... 16, 2011  Senior citizens and people living with physical ... power wheelchairs if the Administration enacts a restrictive prepayment ... Medicare system, according to consumer advocates and home medical ... Centers for Medicare and Medicaid Services (CMS) has listed ...
... 16, 2011  Veran Medical Technologies announced today the ... bi-planar virtual fluoroscopy view used to navigate multiple ... its kind in pulmonology, enabling physicians to view ... in a fluoro-like view without any radiation being ...
Cached Medicine Technology:Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 2Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 3Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 4Veran Medical Technologies Launches New SPiN Drive™ Application for Bi-Planar Virtual Fluoroscopy View 2
(Date:10/31/2014)... 31, 2014 This Method to ... health effects for practitioners. , The Hypopresive ... of Science and Movement specializing in physical rehabilitation. ... pelvic floor reeducation that traditional abdominal exercises after ... Recti, Prolepses, etc. , The Hipopressives exercises pull ...
(Date:10/31/2014)... October 31, 2014 Energy Textiles has ... The new gear is now available online, and Energy ... benefits of Celliant infrared-active athletic gear over compression gear. ... another contract has been signed for Under Armour to ... the next eight years. In light of this decision, ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... 2014 Gold Medal Wine Club ... but tasteful gifts for the wine novice and enthusiasts on ... Gift Giving Special , which Early Bird shoppers receive discounts ... Club Gift membership. , Gift Givers must place their ... Besides offering discounts, Gold Medal Wine Club adds more value ...
(Date:10/31/2014)... a drug combination that can trigger the self-destruct process ... new treatments, according to research that will be presented ... in Liverpool next week*. , When healthy cells are ... culminating in self destruction. But cancer cells swerve away ... that cells grow out of control – causing tumours ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... ( www.PatientAssistance.com ) has released initial survey results on diabetes ... ... Baton Rouge, LA – November 20, 2008 – ... awareness amongst the predominantly uninsured and underinsured visitors of ...
... Amy Rees Anderson, was invited to participate with U.S. Secretary of ... Care. , ... Salt Lake City (Vocus) November 20, ... with U.S. Secretary of Health, Michael Leavitt, in the 2008 National ...
... for the prestigious "Super Dentist" award given to elite dentists in ... top practitioner in the area of Cosmetic Dentistry. , ... ... Austin Smiles was recently nominated as a "Texas Monthly ...
... the frequency of exacerbations in patients with moderate to ... as 35 percent, according to a London-based study. ... macrolide therapy, reducing exacerbation frequency and severity with moderate ... Terence A. R. Seemungal, Ph.D., and Jadwiga Wedzicha, M.D., ...
... NEW YORK Nov. 19, 2008 The American ... and largest non-governmental funder of cancer research and discovery ... Honor, to four Americans who have made outstanding contributions ... will receive their awards at a ceremony during the ...
... says about 40% returned positive results in review of ... Colorectal cancer screening detects 40 percent of cancers and ... Finnish Cancer Registry researchers. , They studied 106,000 people, ... colorectal cancer screening program was in identifying unrecognized disease. ...
Cached Medicine News:Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 2Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 3Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 3Health News:Scientists honored for contributions to cancer fight 2Health News:Scientists honored for contributions to cancer fight 3Health News:Scientists honored for contributions to cancer fight 4Health News:Scientists honored for contributions to cancer fight 5Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Medicine Products: